• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Optimal molecular selection to benefit from nivolumab-ipilimumab in clear-cell renal cell carcinoma.

作者信息

Vano Yann-Alexandre, Elaidi Réza, Phan Letuan, Fridman Wolf Herman, Sautès-Fridman Catherine, Oudard Stéphane

机构信息

Department of Medical Oncology, Hoôpital Europeéen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre-Université Paris Cité, 75015 Paris, France (Y-AV, SO); Centre de Recherche des Cordeliers, INSERM, Université Paris Cité, Sorbonne Université, F-75006, Paris, France; INSERM U970, PARCC, 75015 Paris, France.

Association pour la Recherche de Theérapeutiques Innovantes en Canceérologie-ARTIC, Hoôpital Europeéen Georges Pompidou, AP-HP Centre-Université Paris Cité, 75015 Paris, France.

出版信息

Lancet Oncol. 2022 Jul;23(7):e318. doi: 10.1016/S1470-2045(22)00331-X.

DOI:10.1016/S1470-2045(22)00331-X
PMID:35772460
Abstract
摘要

相似文献

1
Optimal molecular selection to benefit from nivolumab-ipilimumab in clear-cell renal cell carcinoma.
Lancet Oncol. 2022 Jul;23(7):e318. doi: 10.1016/S1470-2045(22)00331-X.
2
[Nivolumab combined with ipilimumab versus sunitinib monotherapy-SUNNIFORECAST AN 41/16 of the AUO : A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma].纳武利尤单抗联合伊匹木单抗对比舒尼替尼单药治疗——AUO的SUNNIFORECAST AN 41/16：一项针对既往未接受治疗的晚期（不可切除或转移性）非透明细胞肾细胞癌患者的2期随机开放标签研究
Urologe A. 2017 Jun;56(6):802-803. doi: 10.1007/s00120-017-0397-1.
3
A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.纳武利尤单抗联合伊匹单抗与舒尼替尼一线治疗中低危晚期肾细胞癌的成本效果分析。
Oncologist. 2019 Mar;24(3):366-371. doi: 10.1634/theoncologist.2018-0656. Epub 2019 Feb 1.
4
Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.纳武利尤单抗联合伊匹单抗对比舒尼替尼用于既往未治疗的晚期肾细胞癌：CheckMate 214 研究中日本患者的分析结果，随访时间延长。
Jpn J Clin Oncol. 2020 Jan 24;50(1):12-19. doi: 10.1093/jjco/hyz132.
5
Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective.派姆单抗联合阿昔替尼与纳武利尤单抗联合伊匹单抗作为中高危晚期肾细胞癌的一线治疗：来自巴西私人视角的需要治疗人数分析。
J Med Econ. 2021 Jan-Dec;24(1):291-298. doi: 10.1080/13696998.2021.1883034.
6
Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.纳武利尤单抗联合伊匹单抗与舒尼替尼治疗晚期肾细胞癌的不良事件和成本的时间趋势。
Future Oncol. 2022 Mar;18(10):1219-1234. doi: 10.2217/fon-2021-1109. Epub 2021 Dec 23.
7
Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.尼伏单抗联合伊匹单抗治疗乳头状肾细胞癌患者的疗效一般。
Jpn J Clin Oncol. 2021 Apr 1;51(4):646-653. doi: 10.1093/jjco/hyaa229.
8
First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.一线纳武利尤单抗联合伊匹单抗与舒尼替尼治疗转移性肾细胞癌：成本效果分析。
JAMA Oncol. 2019 Apr 1;5(4):491-496. doi: 10.1001/jamaoncol.2018.7086.
9
[A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma - SUNNIFORECAST AN 41/16 der AUO].
Aktuelle Urol. 2020 Jun;51(3):236-238. doi: 10.1055/a-1079-7621. Epub 2020 Jun 2.
10
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.纳武利尤单抗联合伊匹单抗对比舒尼替尼用于晚期肾细胞癌的一线治疗：来自一项随机、对照、III 期临床试验的疗效和安全性结果的扩展随访。
Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16.

引用本文的文献

1
Combination of Anti-Angiogenics and Immunotherapies in Renal Cell Carcinoma Show Their Limits: Targeting Fibrosis to Break through the Glass Ceiling?抗血管生成药物与免疫疗法联合治疗肾细胞癌的局限性：靶向纤维化能否突破瓶颈？
Biomedicines. 2024 Feb 7;12(2):385. doi: 10.3390/biomedicines12020385.
2
A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma.一组新型 VEGF 剪接变体作为肾细胞癌的替代治疗靶点。
Mol Oncol. 2023 Jul;17(7):1379-1401. doi: 10.1002/1878-0261.13401. Epub 2023 Apr 18.
3
Tailoring treatment in metastatic renal cell carcinoma.
转移性肾细胞癌的个体化治疗
Nat Rev Urol. 2022 Aug;19(8):455-456. doi: 10.1038/s41585-022-00615-z. Epub 2022 Jun 9.